Clozapine
- Atc Codes:N05AH02
- CAS Codes:5786-21-0
- PHARMGKB ID:5786-21-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Lanolept, Leponex; Belgium: Clozapine, Leponex; Bulgaria: Leponex; Cyprus: Clozarem, Leponex; Czech Republic: Clozapin, Leponex; Denmark: Clozapine, Leponex; Estonia: Clozapine, Leponex; Finland: Clozapin, Froidir, Leponex; France: Clozapine, Leponex; Germany: Clozapin, Elcrit, Leponex; Greece: Leponex; Hungary: Clozapine, Leponex; Ireland: Clozalux, Clozaril, Denzapine; Italy: Clozapina, Leponex; Latvia: Clozapine, Leponex; Lituania: Clozapine, Leponex; Luxembourg: Leponex; Malta: Clozarem, Leponex; Netherlands: Clozapine, Leponex; Poland: ClozaLek, Clozapine, Klozapol, Leponex; Portugal: Clozapina, Leponex, Ozapim; Romania: Clozapine, Leponex; Slovakia: Klozapin, Leponex; Slovenia: Clozalux, Leponex; Spain: Leponex; Sweden: Clozapine, Leponex; UK: Clozaril, Denzapine.
North America
Canada: Clozapine, Clozaril; USA: Clozapine, Clozaril, FazaClo ODT.
Latin America
Argentina: Clozapina, Lapenax, Sequax; Brazil: Leponex; Mexico: Clopsine, Leponex.
Drug combinations
Chemistry
Clozapine: C~18~H~19~ClN~4~. Mw: 326.82. (1) 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-; (2) 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine. CAS-5786-21-0 (1969).
Pharmacologic Category
Atypical Antipsychotics. (ATC-Code: N05AH02).
Mechanism of action
Exact mechanism of antipsychotic action not fully elucidated. May involve serotonergic, adrenergic, and cholinergic neurotransmitter systems in addition to more selective, regionally specific effects on the mesolimbic dopaminergic system. Antagonism of histamine H~1~-receptors, cholinergic, and α~1~-adrenergic receptors may contribute to other therapeutic and adverse effects (e.g. constipation, somnolence, orthostatic hypotension).
Therapeutic use
Treatment-refractory schizophrenia. To reduce risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder.
Pregnancy and lactiation implications
Teratogenic effects not seen in animals. There are no adequate studies in pregnant women. Use during pregnancy only if clearly needed. Not recommended during lactation.
Unlabeled use
Schizoaffective disorder, bipolar disorder, childhood psychosis, severe obsessive-compulsive disorder. Psychosis/agitation related to Alzheimer’s dementia.
Contraindications
Hypersensitivity to clozapine or any component of the formulation. History of agranulocytosis or granulocytopenia with clozapine. Uncontrolled epilepsy, severe CNS depression or comatose state. Paralytic ileus. Myeloproliferative disorders or use with other agents which have a well-known risk of agranulocytosis or bone marrow suppression.
Warnings and precautions
Significant risk of agranulocytosis, potentially life-threatening. May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention; use with caution in decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems). Myocarditis, pericarditis, pericardial effusion, cardiomyopathy, and heart failure described. May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Atypical antipsychotics have been associated with development of hyperglycemia (may be associated with ketoacidosis, hyperosmolar coma, or death). Use with caution in diabetes or other disorders of glucose regulation. Use may be associated with neuroleptic malignant syndrome. May cause orthostatic hypotension (with or without syncope) and tachycardia. May be moderate to highly sedating. Seizures have been associated with clozapine use in a dose-dependent manner. Elderly patients may be at increased risk of seizures. The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder. Impaired core body temperature regulation may occur. Rare cases of thromboembolism, including pulmonary embolism and stroke resulting in fatalities, have been associated with clozapine in cardiovascular disease. Significant weight gain observed with antipsychotic therapy. Elderly patients with dementia-related psychosis treated with atypical antipsychotics are at an increased risk of death compared to placebo. Clozapine is not approved for dementia-related psychosis. Use with caution in narrow-angle glaucoma (may be exacerbated by cholinergic blockade). Use with caution in hepatic disease or impairment (hepatitis reported as a consequence of therapy). Use with caution in myasthenia gravis (may be exacerbated by cholinergic blockade). Use with caution in renal impairment. Concurrent use with benzodiazepines may increase the risk of severe cardiopulmonary reactions. Medication should not be stopped abruptly. Cigarette smoking may enhance the metabolism of clozapine.